Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2025-12-25 @ 1:42 PM
NCT ID: NCT02630992
Description: None
Frequency Threshold: 3
Time Frame: Adverse event data were collected through the end-of-treatment visit. The mean day for this visit was 14.2.
Study: NCT02630992
Study Brief: Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Amoxicillin-clavulanate Potassium amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg in two divided doses for 10 days; oral, liquid (formulation 2) 0 None 0 112 38 112 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Protocol defined diarrhea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Diaper dermatitis SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders None View